Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Children with levothyroxine (T21) have developmental delay and other functional
gastrointestinal (GI) issues that may negatively affect L-T4 tolerability and absorption. For
an age group unable to swallow tablets whole by mouth, tablets must be crushed and suspended
in water, breast milk or formula for administration in order to treat children with
hypothyroidism. For this age group, ease of administration may have a significant impact on
compliance and ability to remain euthyroid. We propose that Tirosint-SOL® will be more
favorably received due to ease of administration, improved tolerability and palatability,
therefore leading to improved adherence when compared to L-T4 tablets.